Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Development and validation of a novel CE method for simultaneous analysis of ribociclib, letrozole and ibuprofen (CROSBI ID 725771)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Božić, Josipa ; Mlinarić, Zvonimir ; Turković, Lu ; Nigović, Biljana ; Sertić, Miranda Development and validation of a novel CE method for simultaneous analysis of ribociclib, letrozole and ibuprofen // International conference 19. Ružička days book of abstracts / Babić, Jurislav ; Lauš, Ivana (ur.). Osijek : Zagreb: Prehrambeno tehnološki fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku ; Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI), 2022. str. 112-112

Podaci o odgovornosti

Božić, Josipa ; Mlinarić, Zvonimir ; Turković, Lu ; Nigović, Biljana ; Sertić, Miranda

engleski

Development and validation of a novel CE method for simultaneous analysis of ribociclib, letrozole and ibuprofen

Breast cancer is the most common cancer worldwide while the HR+/HER2- subtype is the most prevalent [1]. Locally advanced or metastatic HR+/HER2- breast cancers are treated with the combination of CDK4/6 inhibitors and drugs with anti-estrogen effects. One of the common combinations used in clinical practice is ribociclib with letrozole [2]. Many breast cancer patients suffer from various comorbidities and side effects. Thus, different drug classes are regularly used in clinical practice, painkiller ibuprofen being one of the most common. Because of that, we developed a capillary electrophoresis (CE) method for the simultaneous determination of ribociclib, letrozole, and ibuprofen since drugs metabolized by the same enzymes can have interactions. During method development, different buffer types (borate and phosphate with and without SDS) and additives and surfactants (SBE-β-CD and i-PrOH) were tested. Separation was achieved with 75 mM phosphate, 8.5 mM sulfobutylether-β-cyclodextrin, and 5% i-PrOH. The optimal conditions were 15 kV, 25 °C and 5 s hydrodynamic injection under 50 mbar. The developed method was validated according to the ICH guidelines and was shown to be linear in the range of 1 to 75 µg mL-1 (r>0.9957). Intra-day and inter-day repeatabilities were evaluated for method precision with acceptable RSD values. The robustness of the method was tested by changing applied voltage (± 0.5 kV), cyclodextrin concentration (± 0.5 mM), and temperature (± 2 ºC) one variable at a time, and the changes in peak areas and migration times were shown to be in the range of 0.34 to 7.27 %. The validated method is the basis for the further development of an even more sensitive method capable of detecting low plasma concentrations of these drugs using innovative sample preparation techniques and coupling to the mass detector which could then be applied to standard clinical practice.

breast cancer, capillary electrophoresis, ribociclib, letrozole, ibuprofen

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

112-112.

2022.

objavljeno

Podaci o matičnoj publikaciji

International conference 19. Ružička days book of abstracts

Babić, Jurislav ; Lauš, Ivana

Osijek : Zagreb: Prehrambeno tehnološki fakultet Sveučilišta Josipa Jurja Strossmayera u Osijeku ; Hrvatsko društvo kemijskih inženjera i tehnologa (HDKI)

2178-6040

Podaci o skupu

19. Ružičkini dani DANAS ZNANOST – SUTRA INDUSTRIJA

poster

19.09.2022-23.09.2022

Vukovar, Hrvatska

Povezanost rada

Farmacija, Kemija